CartiHeal successfully enrolled the 150th patient in the Investigational Device Exemption clinical study of the Agili-C™ implant. This is an increase from the 100th patient milestone achieved at the beginning of 4Q18.
The objective of the ongoing study is to demonstrate superiority of the cell-free Agili-C implant vs. microfracture and debridement in the treatment of cartilage defects, in both arthritic knees and those without degenerative changes.
A minimum of 250 patients is expected to be enrolled within the next nine to 12 months.
CartiHeal successfully enrolled the 150th patient in the Investigational Device Exemption clinical study of the Agili-C™ implant. This is an increase from the 100th patient milestone achieved at the beginning of 4Q18.
The objective of the ongoing study is to demonstrate superiority of the cell-free Agili-C implant vs. microfracture and...
CartiHeal successfully enrolled the 150th patient in the Investigational Device Exemption clinical study of the Agili-C™ implant. This is an increase from the 100th patient milestone achieved at the beginning of 4Q18.
The objective of the ongoing study is to demonstrate superiority of the cell-free Agili-C implant vs. microfracture and debridement in the treatment of cartilage defects, in both arthritic knees and those without degenerative changes.
A minimum of 250 patients is expected to be enrolled within the next nine to 12 months.
Copy to clipboard 
